Showing 1 - 2 results of 2 for search 'Yoko Kayukawa', query time: 0.02s Refine Results
  1. 1
    Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial

    Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial by Shun-ichiro Komatsu, Yoko Kayukawa, Yoko Miyazaki, Akihisa Kaneko, Hisashi Ikegami, Takahiro Ishiguro, Mikiko Nakamura, Werner Frings, Natsuki Ono, Kiyoaki Sakata, Toshihiko Fujii, Shohei Kishishita, Takehisa Kitazawa, Mika Endo, Yuji Sano

    Published 2022-07-01
    Get full text
    Article
  2. 2
    Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours

    Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours by Yuji Sano, Yumiko Azuma, Toshiaki Tsunenari, Yoko Kayukawa, Junko Shinozuka, Etsuko Fujii, Jun Amano, Yukari Nishito, Toru Maruyama, Yasuko Kinoshita, Yuichiro Sakamoto, Ayae Yoshida, Yoko Miyazaki, Yuta Sato, Chifumi Teramoto-Seida, Takahiro Ishiguro, Takayoshi Tanaka, Takehisa Kitazawa, Mika Endo

    Published 2022-09-01
    Get full text
    Article

Search Tools: